



A Simple and Convenient Method for Synthesis of Artemisinin Dimer through Aliphatic Nitro Compounds

NITIN SRIVASTAVA^{1,*}, B.K. RATHORE², R.K. VISHNOI¹ and SANGEETA BAJPAI¹

¹Department of Chemistry, Amity University Uttar Pradesh Lucknow Campus, Lucknow-226028, India

²Department of Chemistry, Fakhruddin Ali Ahmed Government P.G. College, Mahmudabad-261203, India

*Corresponding authors: E-mail: nitinsriv5@gmail.com; sbajpai1@amity.edu

Received: 28 July 2020;

Accepted: 6 September 2020;

Published online: 10 December 2020;

AJC-20175

A simple way of synthesis of artemisinin dimer using nitro aliphatic compounds is reported. Herein, few artemisinin monomers and dimers have been synthesized with the help of linker nitroalkanes using iron catalyst supported on polymer (Fe/SBA-15). The synthesized artemisinin shows good anticancer and antimalarial activities.

Keywords: Substituted aliphatic compounds, Polymer (Fe/SBA-15), Artemisinin dimer, Biological activities.

INTRODUCTION

In the modern methods of organic synthesis, it is found that nitro compounds are useful intermediates and building blocks [1-4]. Such nitro compounds are obtained easily can be conveniently used for the formation of carbon-carbon bond in basic medium and the nitro group can be converted to many desired functional groups. Such convertibility of nitro alkanes to various carbon-carbon bond formations and the criteria's for such reactions have been explored by several researchers [5-8].

Artemisia annua [9] has active compound artemisinin and is very useful antimalarials drug in the case where *Plasmodium falciparum* is resistant to normal drugs for malaria. Besides antimalarial activity, artemisinin derivatives and derived dimers of artemisinin have been found to be significant anticancer drugs [10]. These reasons have made the quest for the exploration of newer synthetic routes for artemisinin dimers inevitable. In this research, a concept of nitroaliphatics in the synthesis of artemisinin dimer has been explored.

The artemisinin dimers are synthesized till now from ethers of dihydroartemisinin and are dimer at C-10 position. It is found that the non-acetal artemisinin derivatives at C-10 are not easily hydrolyzed, have least toxicity [11] and longer half life. Several researchers have explored several approaches for the synthesis of C-10 carba analogues [12]. Artemisinin dimers can be synthe-

sized from naturally occurring artemisitene bond formation at C-16 through Michael addition. Till date Michael addition at C-16 is less explored as far as literature is concerned. This C-16 position of artemisitene has been utilized for Michael addition by Ekthawatchai *et al.* [13] using dithiols and Grignard reagent for the synthesis of artemisinin dimer. Earlier researchers [14-21] have reported the importance of nitroaliphatics in the natural product synthesis. In this communication, dinitroaliphatic compounds as linker at C-16 for the synthesis of artemisinin carbodimers are reported.

EXPERIMENTAL

Polymer support synthesis: The polymer support SBA-15 was synthesized as per the process reported by Zhao *et al.* [22].

Synthesis of catalyst: Iron catalyst supported on polymer *i.e.* Fe/SBA-15 was synthesized by mixing 30 mL of H₂O, 0.03 mmol of FeCl₃ (4.835 mg) and 0.5 g of SBA-15 at ambient temperature for 24 h. The centrifugation of the solution was done for 5 min (4000 rpm). The liquid was decanted and solid remain was dried for 24 h at 100 °C.

Typical procedure: A dry round bottom was charged with 0.6 mmol of artemisitene, 0.5 mmol of dinitro aliphatic compounds, 2.0 mL CDCl₃ and Fe/SBA-15 as catalyst. The entire components were mixed together at 50 °C continuously upto 24 h. When the reaction got over the mixture was brought to 20 °C and solid catalyst then removed through filtration.

Characterization: IR spectra of the compounds covering the range of 4000-200 cm^{-1} , was done on Bomem MB-FTIR machine and ^1H NMR spectra done at 400 MHz, ^{13}C NMR at 100 MHz both on Bruker Advance spectrometer in the solvent CDCl_3 with TMS as standard.

(3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6-dimethyl-9-[2',7'-dinitro octyl-8'-(3R,5aS,6R,8aS,9R,12S,12aR)-octahydro-3,6-dimethyl-3,12-epoxy-12H-pyrano[4,3-*j*]-1,2-benzodioxepin-10(3H)-one]-3,12-epoxy-12H-pyrano[4,3-*j*]-1,2-benzodioxepin-10(3H)-one (3a): White powder, yield 48%, m.p. 194-196 $^\circ\text{C}$; Elemental analysis of $\text{C}_{36}\text{H}_{52}\text{N}_2\text{O}_{14}$ calcd. (found) %: C 58.68 (58.70), H 7.11 (7.18), N 3.80 (3.76). IR (CHCl_3 , ν_{max} , cm^{-1}): 2942 (C-H *str.*), 1735 (C=O *str.*), 1547 (N-O, *asym. str.*), 1372 (br, s, C-O), 1230 (C-O), 700 (CH_2 rocking). ^1H NMR (δ ppm): 0.97 (6H, d, 6 Hz), 1.46 (6H, s), 1.6-1.98 (28H, m), 2.38-2.44 (6H, m), 3.03 (2H, m), 4.62-4.69 (1H, m), 5.02-5.23 (1H, m), 6.02 (1H, s), 6.29 (1H, s); ^{13}C NMR (δ ppm): 171.1, 170.4, 105.5, 105.2, 94.0, 93.1, 87.6, 87.5, 85.6, 80.2, 80.1, 50.2, 45.8, 45.7, 41.9, 41.5, 41.4, 39.6, 37.9, 37.4, 35.8, 34.0, 33.8, 33.7, 30.9, 30.7, 25.4, 25.3, 24.9, 24.6, 19.8; MS (m/z) = 759 [M^+Na].

(3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6-dimethyl-9-[2',7'-dinitro decyl-8'-(3R,5aS,6R,8aS,9R,12S,12aR)-octahydro-3,6-dimethyl-3,12-epoxy-12H-pyrano[4,3-*j*]-1,2-benzodioxepin-10(3H)-one]-3,12-epoxy-12H-pyrano[4,3-*j*]-1,2-benzodioxepin-10(3H)-one (3b): Yellow sticky liquid, yield 52%; Elemental analysis of $\text{C}_{38}\text{H}_{56}\text{N}_2\text{O}_{14}$ calcd. (found) %: C 59.67 (59.49), H 7.38 (7.31), N 3.66 (3.75). IR (CHCl_3 , ν_{max} , cm^{-1}): 2945 (C-H *str.*), 1736 (C=O *str.*), 1546 (N-O, *asym. str.*), 1372 (br, s), 1230 (C-O), 708 (CH_2 rocking); ^1H NMR (δ ppm): 1.01-1.10 (6H, d), 1.29-1.37 (2H, m), 1.99 (6H, s), 2.20-2.28 (2H, m), 2.66-2.86 (22H, m), 3.02-3.18 (6H, m), 3.39-3.42 (6H, m), 4.02 (2H, m), 5.00-5.08 (2H, m), 6.05 (2H, s); ^{13}C NMR (δ ppm): 171, 105.4, 94.1, 87.8, 80.0, 50.2, 45.8, 41.6, 39.7, 37.5, 37.1, 35.8, 34.4, 33.7, 32.7, 31.9, 30.7, 30.0, 29.7, 29.4, 28.6, 25.4, 25.3, 24.6, 22.7, 19.8, 14.1; MS (m/z) = 764.3 (M^+).

(3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6-dimethyl-9(2',7'-dinitro heptyl)-3,12-epoxy-12H-pyrano[4,3-*j*]-1,2-benzodioxepin-10(3H)-one (4): Colourless liquid, yield 40%; $[\alpha]_{\text{D}}^{20}$ (CHCl_3 , c 1.0) = +29.8; Elemental analysis of $\text{C}_{21}\text{H}_{32}\text{N}_2\text{O}_9$ calcd. (found) %: C 55.25 (55.19), H 7.07 (7.10), N 6.14 (6.18). IR (CHCl_3 , ν_{max} , cm^{-1}): 2946 (C-H *str.*), 1735 (C=O *str.*), 1549 (N-O, *asym. str.*), 1370 (C-O br, s), 1232 (w, C-O), 710 (CH_2 rocking); ^1H NMR (δ ppm): 0.88 (3H, d, 5.8 Hz), 1.50 (3H, s), 2.36-2.60 (22H, m), 3.05 (2H, t, 7.0 Hz), 5.09-5.18 (1H, m), 6.03 (1H, s); ^{13}C NMR (δ ppm): 171.2, 105.4, 94.0, 87.3, 80.1, 75.3, 66.8, 50.2, 45.9, 41.5, 39.7, 37.5, 35.8, 34.0, 33.7, 30.7, 26.9, 25.6, 25.4, 24.9, 19.8; MS (m/z) = 456.1 (M^+).

1,5-Dinitro-pentan-2-ol (5): Yellow sticky liquid, yield 49%; Elemental analysis for $\text{C}_5\text{H}_{10}\text{N}_2\text{O}_5$ calcd. (found) %: C 33.71 (33.78), H 5.66 (5.70), N 15.73 (15.72). IR (CHCl_3 , ν_{max} , cm^{-1}): 3431 (O-H *str.*), 2928 (C-H *str.*), 1552 (N-O, *asym. str.*); ^1H NMR (δ ppm): 4.41-4.72 (5H, m, CHOH , NO_2CH_2), 2.12-2.29 (2H, m, $\text{CH}_2\text{CH}_2\text{-OH}$), 2.18 (1H, s, O-H); ^{13}C NMR (δ ppm): 81.0, 75.3, 67.9, 30.2, 25.2; MS (m/z) = 178 (M^+).

2-(4-Nitro-1-nitromethyl-butoxy)tetrahydropyran (6): Yellow sticky liquid, yield 68%; Elemental analysis of $\text{C}_{10}\text{H}_{18}\text{N}_2\text{O}_6$ calcd. (found) %: C 45.79 (45.74), H 6.92 (6.88), N 10.68 (10.72). IR (CHCl_3 , ν_{max} , cm^{-1}): 2952 (C-H *str.*), 1552 (N-O, *asym. str.*), 1131 (C-O *str.*), 1034 (CH_2 twist), 981 (C-C-C); ^1H NMR (δ ppm): 1.28-1.81 (6H, m, CH_2THP), 2.18-2.32 (4H, m, CH_2), 3.62 (1H, m, HCO), 3.91 (2H, m, HCO , HCOTHP), 4.40-4.56 (4H, m, NO_2CH_2), 4.71-4.90 (1H, m, OCHO); ^{13}C NMR (δ ppm): 100.0, 79.1, 74.9, 73.8, 64.0, 30.9, 29.6, 25.0, 22.9, 20.2; MS (m/z) = 262 (M^+).


(3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6-diimethyl-9-[2',6'-dinitro-5-(2-tetrahydro-pyran)heptyl 7'-(3R,5aS,6R,8aS,9R,12S,12aR)-octahydro-3,6-dimethyl-3,12-epoxy-12H-pyrano[4,3-*j*]-1,2-benzodioxepin-10(3H)-one]-3,12-epoxy-12H-pyrano[4,3-*j*]-1,2-benzodioxepin-10(3H)-one (7): Pale yellow Sticky liquid, yield 51%; Elemental analysis of $\text{C}_{40}\text{H}_{58}\text{N}_2\text{O}_{16}$ calcd. (found) %: C 58.38 (58.31), H 7.10 (7.08), N 3.40 (3.45). IR (CHCl_3 , ν_{max} , cm^{-1}): 2942 (C-H *str.*), 1737 (C=O *str.*), 1550 (N-O, *asym. str.*), 1372 (br, s), 1230 (C-O), 700 (CH_2 rocking); ^1H NMR (δ ppm): 0.78 (3H, d, 6 Hz), 0.94 (3H, d, 6 Hz), 1.07 (6H, s), 1.98-2.18 (36H, m), 3.01 (2H, m), 2.28 (1H, m), 3.96 (1H, m), 4.30-4.36 (3H, m), 4.99-5.26 (1H, m), 6.03 (1H, s), 6.19 (1H, s); ^{13}C NMR (δ ppm): 171.1, 170.8, 105.4, 99.3, 99.2, 94.1, 94.0, 87.3, 87.1, 80.1, 80.0, 79.0, 78.9, 73.7, 73.3, 62.9, 50.2, 45.8, 41.5, 39.7, 39.6, 37.4, 35.8, 33.7, 30.9, 30.7, 30.6, 29.8, 29.6, 27.9, 25.4, 25.0, 24.6, 20.4, 19.7, 19.5; MS (m/z) = 734.8 ($\text{M}^+\text{-THP}$).

(3R,5aS,6R,8aS,9R,12S,12aR)-Octahydro-3,6-dimethyl-9-[2',6'-dinitro-5-(2-tetrahydro-pyran)hexyl]-3,12-epoxy-12H-pyrano[4,3-*j*]-1,2-benzodioxepin-10(3H)-one (8): Light yellow sticky liquid, yield 55%; Elemental analysis for $\text{C}_{25}\text{H}_{38}\text{N}_2\text{O}_{11}$ calcd. (found) %: C 55.34 (55.29), H 7.06 (7.03), N 5.16 (5.19). IR (CHCl_3 , ν_{max} , cm^{-1}): 2942 (C-H *str.*), 1737 (C=O *str.*), 1550 (N-O, *asym. str.*), 1208 (C-O *str.*), 1034 (CH_2 twist); ^1H NMR (δ ppm): 1.02 (3H, d, 6 Hz), 1.19 (3H, s), 1.28-1.37 (23H, m), 2.79 (2H, m), 3.03 (1H, m), 3.80 (1H, m), 3.98-4.12 (2H, m), 5.05-5.23 (2H, m), 5.96 (1H, s); ^{13}C NMR (δ ppm): 170.4, 170.8, 104.5, 100.2, 99.1, 93.9, 87.3, 80.2, 79.0, 73.8, 73.1, 63.0, 50.1, 46.0, 41.6, 40.1, 39.6, 37.4, 36.0, 33.7, 31.0, 30.7, 30.5, 30.0, 29.6, 28.1, 25.4, 25.1, 24.8, 20.2, 19.8, 19.1; MS (m/z) = 541.9 (M^+).

RESULTS AND DISCUSSION

In first step, open chain aliphatic dihalides was treated with sodium nitrite which led to the formation of open chain dinitro compounds (**Scheme-I**) [22]. Open chain dibromo-aliphatic compounds **1a** ($n=4$) and **1b** ($n=6$) were treated with sodium nitrite in aqueous medium yielded dinitrohexane **2a** ($n=4$) and **2b** ($n=6$), respectively in 60-70% yield after 36 h.


In next step, an increment of C-C bond at α,β -unsaturated lactone moiety through Michael addition in artemisitene was




Scheme-I

achieved in the presence of Lewis acid like AlCl_3 , FeCl_3 , *etc.* In present work, iron impregnated polymer was used as a catalysts, where artemisitene undergoes Michael addition reaction with open chain dinitro compounds whose terminal H was substituted with nitro group (**2a** and **2b**) in the presence of polymer based catalyst Fe/SBA-15 at 50°C to generate artemisinin dimers **3a** ($n = 4$) and **3b** ($n = 6$) as shown in **Scheme-II**.

Substituted artemisinin with dinitro group (**4**) and the dimer **3a** can be easily isolated in case of 1,6-dinitrohexane. Among the various Lewis acids like AlCl_3 , SiCl_4 , and the bases like sodium hydride, triethyl amine, DBU, *etc.* none was able to perform the Michael addition reaction on artemisitene with these nitroaliphatics. But SBA-15 supported FeCl_3 gave the reaction fast and with better yield. A stereochemistry at C-9 of artemisinin is assigned because, the peak for C-9 proton in artemisinin ($\delta = 3.46$ ppm) was found to be shifting upfield with $\delta < 3.0$ ppm in the NMR spectra of compounds **3a**, **3b** and **4**, which is verified with the documented ^1H NMR data of artemisinin molecule along with its analogues and thus confirmed that a stereochemistry associated with C-9 proton.



Scheme-II



Scheme-III

TABLE-1
INHIBITION OF PROLIFERATION OF DIFFERENT CANCER CELL LINES

Compounds	Conc. (M)	Lung	CNS	Prostrate	Leukemia	Colon
		A-549	SF-295	PC-3	THP-1	Colo-205
3a	10	2	3	0	7	18
7	10	14	24	9	40	25
4	10	0	0	6	10	9
Adriamycin	1	NA	70	NA	NA	NA
Paclitaxel	10	65	NA	NA	NA	NA
Mitomycin	10	NA	NA	68	NA	NA
5-Fluorouracil	20		NA	NA	70	55

NA = Compounds not exposed to cancer cell lines.

of these compounds against chloroquine sensitive *P. falciparum* strain were also found comparable to that of artemisinin (Table-2).

Compounds	Dosage (µg/mL)	% Dead rings + schizonts (mean of three replicates)
3a	0.1	22.4
4	0.1	10.1
7	0.1	40.0
8	0.1	12.0
Artemisinin	0.1	58.2

Conclusion

A novel simple and greener synthetic method for synthesizing artemisinin dimers by employing nitroaliphatics as linkers containing two nitro groups is successfully accomplished. The process may be further employed for making artemisinin derivatives.

CONFLICT OF INTEREST

The authors declare that there is no conflict of interests regarding the publication of this article.

REFERENCES

- A.Y. Sukhorukov, *Front. Chem.*, **8**, 595246 (2020); <https://doi.org/10.3389/fchem.2020.595246>
- G. Yan and M. Yang, *Org. Biomol. Chem.*, **11**, 2554 (2013); <https://doi.org/10.1039/C3OB27354G>
- R. Ballini and M. Petrini, *Arkivoc*, 195 (2009); <https://doi.org/10.3998/ark.5550190.0010.912>
- N. Nishiwaki, *Molecules*, **25**, 3680 (2020); <https://doi.org/10.3390/molecules25163680>
- R. Ballini, S. Gabrielli, A. Palmieri and M. Petrini, *Curr. Org. Chem.*, **15**, 1482 (2011); <https://doi.org/10.2174/138527211795378137>
- R. Ballini and A. Palmieri, *Curr. Org. Chem.*, **10**, 2145 (2006); <https://doi.org/10.2174/138527206778742632>
- C. Czekelius and E.M. Carreira, *Angew. Chem. Int. Ed.*, **44**, 612 (2005); <https://doi.org/10.1002/anie.200461879>
- R. Ballini and A. Palmieri, *Adv. Synth. Catal.*, **361**, 5070 (2019); <https://doi.org/10.1002/adsc.201900563>
- A. Septembre-Malaterre, M.L. Rakoto, C. Marodon, Y. Bedoui, J. Nakab, E. Simon, L. Hoarau, S. Savriama, D. Strasberg, P. Guiraud, J. Selambarom and P. Gasque, *Int. J. Mol. Sci.*, **21**, 4986 (2020); <https://doi.org/10.3390/ijms21144986>
- D. Chaturvedi, A. Goswami, P.P. Saikia, N.C. Barua and P.G. Rao, *Chem. Soc. Rev.*, **39**, 435 (2010); <https://doi.org/10.1039/B816679J>
- M. Jung, X. Li, D.A. Bustos, H.N. ElSohly, J.D. McChesney and W.K. Milhous, *J. Med. Chem.*, **33**, 1516 (1990); <https://doi.org/10.1021/jm00167a036>
- G.H. Posner, P. Ploypradith, M.H. Parker, H. O'Dowd, S.H. Woo, J. Northrop, M. Krasavin, P. Dolan, T.W. Kensler, S. Xie and T.A. Shapiro, *J. Med. Chem.*, **42**, 4275 (1999); <https://doi.org/10.1021/jm990363d>
- S. Ekthawatchai, S. Kamchonwongpaisan, P. Kongsaree, B. Tarnchompoo, Y. Thebtaranonth and Y. Yuthavong, *J. Med. Chem.*, **44**, 4688 (2001); <https://doi.org/10.1021/jm0103007>
- D. Kalita, A.T. Khan, N.C. Barua and G. Bez, *Tetrahedron*, **55**, 5177 (1999); [https://doi.org/10.1016/S0040-4020\(99\)00164-7](https://doi.org/10.1016/S0040-4020(99)00164-7)
- B. Kalita, N.C. Barua, M.S. Bezbarua and G. Bez, *Synlett*, 1411 (2001); <https://doi.org/10.1055/s-2001-16776>
- J.C. Borah, S. Gogoi, J. Boruwa, B. Kalita and N.C. Barua, *Tetrahedron Lett.*, **45**, 3689 (2004); <https://doi.org/10.1016/j.tetlet.2004.02.150>
- N. Gogoi, J. Boruwa and N.C. Barua, *Tetrahedron Lett.*, **46**, 7581 (2005); <https://doi.org/10.1016/j.tetlet.2005.08.153>
- J. Boruwa and N.C. Barua, *Tetrahedron*, **62**, 1193 (2006); <https://doi.org/10.1016/j.tet.2005.10.070>
- N. Gogoi, J. Boruwa and N.C. Barua, *Eur. J. Org. Chem.*, 1722 (2006); <https://doi.org/10.1002/ejoc.200500833>
- P.P. Saikia, G. Baishya, A. Goswami and N.C. Barua, *Tetrahedron Lett.*, **49**, 6508 (2008); <https://doi.org/10.1016/j.tetlet.2008.08.113>
- A. Goswami, P.P. Saikia, N.C. Barua, M.J. Bordoloi, A. Yadav, T.C. Bora, B.K. Gogoi, A.K. Saxena, N. Suri and M. Sharma, *Bioorg. Med. Chem. Lett.*, **20**, 359 (2010); <https://doi.org/10.1016/j.bmcl.2009.10.097>
- R. Ballini, L. Barboni and G. Giarlo, *J. Org. Chem.*, **69**, 6907 (2004); <https://doi.org/10.1021/jo049048b>